Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies

Phase I Study of the Focal Adhesion Kinase Inhibitor BI 853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors

(2019) Toshihiko Doi et al.   Targeted Oncology

Efficacy of the highly selective focal adhesion kinase inhibitor BI 853520 in adenocarcinoma xenograft models is linked to a mesenchymal tumor phenotype

(2018) Ulrich A. Hirt et al.   Oncogenesis

Phase I study of defactinib combined with pembrolizumab and gemcitabine in patients with advanced cancer.

(2018) Andrea Wang-Gillam et al.   JOURNAL OF CLINICAL ONCOLOGY

The FAK inhibitor BI 853520 exerts anti-tumor effects in breast cancer

(2018) Stefanie Tiede et al.   Oncogenesis

A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors

(2016) J. C. Soria et al.   ANNALS OF ONCOLOGY

A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors

(2016) Toshio Shimizu et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Molecular Pathways: Endothelial Cell FAK--A Target for Cancer Treatment

(2016) M. Roy-Luzarraga et al.   CLINICAL CANCER RESEARCH

CT-707, a Novel FAK Inhibitor, Synergizes with Cabozantinib to Suppress Hepatocellular Carcinoma by Blocking Cabozantinib-Induced FAK Activation

(2016) Dan-Dan Wang et al.   MOLECULAR CANCER THERAPEUTICS

Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy

(2016) Hong Jiang et al.   NATURE MEDICINE

Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity

(2015) Alan Serrels et al.   CELL

Anti-metastatic action of FAK inhibitor OXA-11 in combination with VEGFR-2 signaling blockade in pancreatic neuroendocrine tumors

(2015) Ingrid Moen et al.   CLINICAL & EXPERIMENTAL METASTASIS

A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors

(2015) Suzanne F. Jones et al.   INVESTIGATIONAL NEW DRUGS

FAK signaling in human cancer as a target for therapeutics

(2015) Brian Y. Lee et al.   PHARMACOLOGY & THERAPEUTICS

Down-Regulation of Integrin β1 and Focal Adhesion Kinase in Renal Glomeruli under Various Hemodynamic Conditions

(2014) Xiaoli Yuan et al.   PLoS One

The role of FAK in tumor metabolism and therapy

(2013) Jianliang Zhang et al.   PHARMACOLOGY & THERAPEUTICS

387 The Focal Adhesion Kinase Inhibitor GSK2256098: a Potent and Selective Inhibitor for the Treatment of Cancer

(2012) K.R. Auger et al.   EUROPEAN JOURNAL OF CANCER

Safety, Pharmacokinetic, and Pharmacodynamic Phase I Dose-Escalation Trial of PF-00562271, an Inhibitor of Focal Adhesion Kinase, in Advanced Solid Tumors

(2012) Jeffrey R. Infante et al.   JOURNAL OF CLINICAL ONCOLOGY

Abstract A249: BI 853520, a potent and highly selective inhibitor of protein tyrosine kinase 2 (focal adhesion kinase), shows efficacy in multiple xenograft models of human cancer.

(2012) U. A. Hirt et al.   MOLECULAR CANCER THERAPEUTICS

Inhibition of Podocyte FAK Protects against Proteinuria and Foot Process Effacement

(2010) H. Ma et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

EMT, the cytoskeleton, and cancer cell invasion

(2009) Mahmut Yilmaz et al.   CANCER AND METASTASIS REVIEWS

Signal transduction by focal adhesion kinase in cancer

(2009) Jihe Zhao et al.   CANCER AND METASTASIS REVIEWS

Dual focal adhesion kinase/Pyk2 inhibitor has positive effects on bone tumors

(2008) Cedo M. Bagi et al.   CANCER

Antitumor Activity and Pharmacology of a Selective Focal Adhesion Kinase Inhibitor, PF-562,271

(2008) W. G. Roberts et al.   CANCER RESEARCH

Focal Adhesion Kinase: Targeting Adhesion Signaling Pathways for Therapeutic Intervention

(2008) J. T. Parsons et al.   CLINICAL CANCER RESEARCH

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER